Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma

R. F. Lemanske, R. F. Lockey, K. R. Murphy (Madison, Tampa, Omaha, United States Of America)

Source: Annual Congress 2004 - Therapy in paediatric asthma II
Session: Therapy in paediatric asthma II
Session type: Thematic Poster Session
Number: 2355
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. F. Lemanske, R. F. Lockey, K. R. Murphy (Madison, Tampa, Omaha, United States Of America). Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma. Eur Respir J 2004; 24: Suppl. 48, 2355

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS)
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004

Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003

A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003

Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma
Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Year: 2019


The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

Effects of mometasone furoate dry powder inhaler administered once-daily in the evening on symptom control in mild to moderate asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 282s
Year: 2003

A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Does health-related quality of life improve with QD and BID dosing of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids?
Source: Eur Respir J 2003; 22: Suppl. 45, 283s
Year: 2003

Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 429s
Year: 2002

Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R)
Source: Eur Respir J 2001; 17: 1332-1333
Year: 2001


Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003

QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma
Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Year: 2020


Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 282s
Year: 2003

LATE-BREAKING ABSTRACT: Bronchodilation with mometasone furoate/formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma
Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases
Year: 2012

Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012